Published in Curr Treat Options Neurol on July 01, 2005
Reduced glioma infiltration in Src-deficient mice. J Neurooncol (2006) 1.29
Novel dual-reporter preclinical screen for antiastrocytoma agents identifies cytostatic and cytotoxic compounds. J Biomol Screen (2008) 0.90
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med (2000) 12.34
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg (2001) 11.58
Cancer statistics, 2002. CA Cancer J Clin (2002) 10.79
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol (1999) 8.69
Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst (1993) 7.87
The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol (2004) 5.43
Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet (2002) 5.21
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol (2003) 4.17
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res (2004) 3.47
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol (1999) 3.30
Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst (1999) 3.25
Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol (2004) 3.25
Factors influencing survival in high-grade gliomas. Semin Oncol (2003) 2.93
PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst (2001) 2.90
Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys (1998) 2.77
Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol (2002) 2.39
Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2000) 2.32
Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res (2001) 2.28
Current management of glioblastoma multiforme. Semin Oncol (2004) 1.83
Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg (2000) 1.82
Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res (2002) 1.82
Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res (2003) 1.79
Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. AJNR Am J Neuroradiol (2001) 1.73
Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol (1998) 1.61
The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors. Neurosurgery (1990) 1.61
Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol (2001) 1.53
Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery (2002) 1.45
Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys (2000) 1.32
Perspectives on the development of a molecularly targeted agent. Cancer Cell (2002) 1.21
Prospective clinical trials of intracranial low-grade glioma in adults and children. Neuro Oncol (2003) 1.21
The course of seizure disorders in patients with malignant gliomas. Arch Neurol (1995) 1.18
Age and radiation response in glioblastoma multiforme. Neurosurgery (2001) 1.16
Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy. Cancer Chemother Pharmacol (1998) 1.14
Practical guidelines for the treatment of malignant gliomas. West J Med (1998) 1.11
Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol (1983) 1.10
In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Radiology (2002) 1.09
Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer (1997) 1.09
Visibility of calcium on MR and CT: can MR show calcium that CT cannot? AJNR Am J Neuroradiol (1994) 1.02
Advances in molecular therapies in patients with brain tumors. Cancer Control (2003) 1.00
Genetic markers in glioblastoma: prognostic significance and future therapeutic implications. Adv Anat Pathol (2003) 1.00
Volume MRI and MRSI techniques for the quantitation of treatment response in brain tumors: presentation of a detailed case study. J Magn Reson Imaging (1998) 0.98
A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene (2004) 0.97
Clinical prognostic factors in patients with malignant glioma treated with combined modality approach. Am J Clin Oncol (2004) 0.93
Current controversies in the radiotherapeutic management of adult low-grade glioma. Semin Oncol (2004) 0.90
Venous thromboembolism and high grade gliomas. Thromb Haemost (1993) 0.90
Monitoring individual response to brain-tumour chemotherapy: proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy. Neuroradiology (2003) 0.89
Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism. J Neurosurg (1987) 0.87
Monoclonal antibody therapy of human gliomas: current status and future approaches. Cancer Metastasis Rev (1999) 0.86
EGFRvIII as a promising target for antibody-based brain tumor therapy. Brain Tumor Pathol (2000) 0.85
Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. J Cancer Res Clin Oncol (2003) 0.85
Epilepsy and gliomas: incidence and treatment in 119 patients. J Exp Clin Cancer Res (1998) 0.84
Diagnosis and treatment of progressive space-occupying radiation necrosis following stereotactic radiosurgery for brain metastasis: value of proton magnetic resonance spectroscopy. Acta Neurochir (Wien) (2003) 0.83
Adenovirus-mediated p53 gene therapy for human gliomas. Neurosurgery (1999) 0.83
Role of radiation therapy and radiosurgery in glioblastoma multiforme. Cancer J (2003) 0.83
Chemotherapy for the treatment of oligodendroglial tumors. Semin Oncol (2001) 0.82
Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: the past decade and where we are heading. Neuro Oncol (1999) 0.81
Perspectives in the treatment of malignant gliomas in adults. Anticancer Res (2002) 0.78
Therapy for recurrent malignant glioma in adults. Expert Rev Anticancer Ther (2004) 0.78
Chemotherapy of oligodendroglial tumours: current developments. Forum (Genova) (2000) 0.76
Proton magnetic resonance spectroscopy-guided biopsy for cerebral glial tumors. J Formos Med Assoc (2004) 0.76
Chemotherapy of low-grade gliomas. Semin Radiat Oncol (2001) 0.75
Chemotherapy for low-grade gliomas. Forum (Genova) (2000) 0.75
Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys (2011) 2.18
Treatment of spinal cord tumors. Curr Treat Options Neurol (2009) 0.81
Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer (2011) 0.78